SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Cash & Equivalents Over TimeContracting
Percentile Rank33
3Y CAGR-11.3%
5Y CAGR-3.6%
Studio
Year-over-Year Change

Cash on hand plus short-term liquid investments

3Y CAGR
-11.3%/yr
Annual compound
5Y CAGR
-3.6%/yr
Recent deceleration
Percentile
P33
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
2025$10.50M+18.0%
2024$8.90M-84.3%
2023$56.57M+275.9%
2022$15.05M-54.7%
2021$33.21M+163.3%
2020$12.61M+98.7%
2019$6.35M-